TABLE 3.
Serum levels of anti-rSAL-1 antibodies determined at the 50-day poststudy visit in each participant
| Participant identification code | Treatment | Dose (mg/kg) | Antibody levela (μg/ml) |
|---|---|---|---|
| R101 | Activeb | 0.1 | NQ |
| R102 | Active | 0.1 | NA |
| R103 | Placebo | 0.1 | NQ |
| R104 | Active | 0.1 | NQ |
| R201 | Active | 0.3 | NQ |
| R202 | Active | 0.3 | NQ |
| R203 | Active | 0.3 | 2.833 |
| R204 | Placebo | 0.3 | NQ |
| R205 | Active | 0.3 | NQ |
| R206 | Placebo | 0.3 | NQ |
| R207 | Active | 0.3 | NQ |
| R208 | Active | 0.3 | NQ |
| R301 | Placebo | 1 | NQ |
| R302 | Active | 1 | NQ |
| R303 | Active | 1 | NQ |
| R304 | Active | 1 | NQ |
| R305 | Placebo | 1 | NQ |
| R306 | Active | 1 | 1.916 |
| R307 | Active | 1 | 3.562 |
| R308 | Active | 1 | 2.035 |
| R401 | Active | 3 | 12.055 |
| R402 | Active | 3 | NQ |
| R403 | Placebo | 3 | NQ |
| R404 | Active | 3 | NQ |
| R405 | Active | 3 | 5.326 |
| R406 | Active | 3 | NA |
| R407 | Placebo | 3 | NQ |
| R408 | Active | 3 | 3.759 |
| R501 | Active | 10 | NQ |
| R502 | Active | 10 | 9.990 |
| R503 | Active | 10 | NQ |
| R504 | Placebo | 10 | NQ |
| R505 | Active | 10 | 4.684 |
| R506 | Active | 10 | NQ |
| R507 | Placebo | 10 | NQ |
| R508 | Active | 10 | 5.068 |
a
NQ, not quantifiable as the value was less than the LLOQ (1.563 μg/ml); NA, not assayed, as a sample was unavailable.
b
Active, active pharmaceutical ingredient.